Don't Rush to Recommend Olumiant or Xeljanz XR for Rheumatoid Arthritis

Olumiant (baricitinib) and Xeljanz XR (tofacitinib) will be new once-daily oral meds for rheumatoid arthritis (RA).

Olumiant (oh-LOO-mee-ant) is the second Janus kinase (JAK) inhibitor for RA on the market after Xeljanz.

And now once-daily Xeljanz XR may simplify dosing over Xeljanz BID.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote